Singapore markets open in 1 hour 43 minutes

Acelyrin, Inc. (SLRN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.2500+0.0700 (+1.67%)
At close: 04:00PM EDT
4.2500 0.00 (0.00%)
After hours: 06:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.1800
Open4.2200
Bid4.2300 x 300
Ask4.3000 x 100
Day's range4.1900 - 4.3800
52-week range4.1400 - 29.8800
Volume1,137,352
Avg. volume1,245,193
Market cap420.38M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-5.4300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.17
  • GlobeNewswire

    ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

    LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to discuss its first quarter 2024 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company’s website under Events & Presentations. A r

  • Simply Wall St.

    Acelyrin Insiders Placed Bullish Bets Worth US$2.65m

    Quite a few insiders have dramatically grown their holdings in Acelyrin, Inc. ( NASDAQ:SLRN ) over the past 12 months...

  • GlobeNewswire

    ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

    Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high statistical significance in global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis with robust clinical responses also achieved for higher hurdle endpoints Announced differentiated long-term 32-week data from global Phase 2b clinical trial of izokibep in hidradenitis suppurativa – ongoi